Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Dec. 31, 2017 | Jan. 31, 2018 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Dec. 31, 2017 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q2 | |
Entity Registrant Name | ALLIED HEALTHCARE PRODUCTS INC | |
Entity Central Index Key | 874,710 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | AHPI | |
Entity Common Stock, Shares Outstanding | 4,013,537 |
STATEMENT OF OPERATIONS
STATEMENT OF OPERATIONS - USD ($) | 3 Months Ended | 6 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Net sales | $ 8,718,602 | $ 8,268,978 | $ 16,615,455 | $ 16,709,391 |
Cost of sales | 6,809,684 | 6,573,722 | 13,349,469 | 13,456,965 |
Gross profit | 1,908,918 | 1,695,256 | 3,265,986 | 3,252,426 |
Selling, general and administrative expenses | 2,153,050 | 2,068,657 | 4,277,518 | 4,442,776 |
Loss from operations | (244,132) | (373,401) | (1,011,532) | (1,190,350) |
Other (income) expenses: | ||||
Interest income | (10) | (334) | (225) | (986) |
Other, net | 185 | 1,633 | 236 | 1,671 |
Nonoperating Income (Expense) | 175 | 1,299 | 11 | 685 |
Loss before income taxes | (244,307) | (374,700) | (1,011,543) | (1,191,035) |
Provision for income taxes | 136,386 | 0 | 136,386 | 0 |
Net loss | $ (380,693) | $ (374,700) | $ (1,147,929) | $ (1,191,035) |
Basic loss per share | $ (0.09) | $ (0.09) | $ (0.29) | $ (0.30) |
Diluted loss per share | $ (0.09) | $ (0.09) | $ (0.29) | $ (0.30) |
Weighted average shares outstanding - basic | 4,013,537 | 4,013,537 | 4,013,537 | 4,013,537 |
Weighted average shares outstanding - diluted | 4,013,537 | 4,013,537 | 4,013,537 | 4,013,537 |
BALANCE SHEET
BALANCE SHEET - USD ($) | Dec. 31, 2017 | Jun. 30, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 800 | $ 995,704 |
Accounts receivable, net of allowances of $170,000 | 3,573,712 | 3,362,438 |
Inventories, net | 9,106,188 | 8,511,954 |
Income tax receivable | 19,688 | 12,555 |
Other current assets | 243,492 | 315,678 |
Total current assets | 12,943,880 | 13,198,329 |
Property, plant and equipment, net | 5,278,595 | 5,734,041 |
Deferred income taxes | 547,377 | 683,763 |
Other assets, net | 0 | 20,516 |
Total assets | 18,769,852 | 19,636,649 |
Current liabilities: | ||
Accounts payable | 2,079,731 | 1,440,403 |
Other accrued liabilities | 1,650,417 | 2,009,966 |
Total current liabilities | 3,730,148 | 3,450,369 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock; $0.01 par value; 30,000,000 shares authorized; 5,213,902 shares issued at December 31, 2017 and June 30, 2017; 4,013,537 shares outstanding at December 31, 2017 and June 30, 2017 | 52,139 | 52,139 |
Additional paid-in capital | 48,486,743 | 48,485,390 |
Accumulated deficit | (12,518,390) | (11,370,461) |
Less treasury stock, at cost; 1,200,365 shares at December 31, 2017 and June 30, 2017, respectively | (20,980,788) | (20,980,788) |
Total stockholders’ equity | 15,039,704 | 16,186,280 |
Total liabilities and stockholders’ equity | 18,769,852 | 19,636,649 |
Series A Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Preferred stock | $ 0 | $ 0 |
BALANCE SHEET _Parenthetical_
BALANCE SHEET [Parenthetical] - USD ($) | Dec. 31, 2017 | Jun. 30, 2017 |
Allowances for accounts receivable (in dollars) | $ 170,000 | $ 170,000 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 1,500,000 | 1,500,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 30,000,000 | 30,000,000 |
Common stock, shares issued | 5,213,902 | 5,213,902 |
Common stock, shares outstanding | 4,013,537 | 4,013,537 |
Treasury stock, at cost | 1,200,365 | 1,200,365 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 200,000 | 200,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
STATEMENT OF CASH FLOWS
STATEMENT OF CASH FLOWS - USD ($) | 6 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flows from operating activities: | ||
Net loss | $ (1,147,929) | $ (1,191,035) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 475,962 | 562,963 |
Stock based compensation | 1,353 | 1,202 |
Provision for doubtful accounts and sales returns and allowances | 1,076 | 10,641 |
Deferred taxes | 136,386 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (212,350) | 816,950 |
Inventories | (594,234) | 24,321 |
Income tax receivable | (7,133) | (6,297) |
Other current assets | 72,186 | 39,633 |
Accounts payable | 639,328 | (500,377) |
Other accrued liabilities | (359,549) | (602,974) |
Net cash used in operating activities | (994,904) | (844,973) |
Cash flows from investing activities: | ||
Capital expenditures | 0 | (11,497) |
Net cash used in investing activities | 0 | (11,497) |
Net decrease in cash and cash equivalents | (994,904) | (856,470) |
Cash and cash equivalents at beginning of period | 995,704 | 1,703,663 |
Cash and cash equivalents at end of period | $ 800 | $ 847,193 |
Summary of Significant Accounti
Summary of Significant Accounting and Reporting Policies | 6 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017. In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance. This new guidance, will likely result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments. |
Inventories
Inventories | 6 Months Ended |
Dec. 31, 2017 | |
Inventory, Net [Abstract] | |
Inventory Disclosure [Text Block] | 2. Inventories Inventories are comprised as follows: December 31, 2017 June 30, 2017 Work-in progress $ 472,699 $ 468,839 Component parts 7,902,227 7,271,908 Finished goods 2,320,593 2,368,855 Reserve for obsolete and excess inventories (1,589,331) (1,597,648) $ 9,106,188 $ 8,511,954 |
Earnings per share
Earnings per share | 6 Months Ended |
Dec. 31, 2017 | |
Earnings Per Share [Abstract] | |
Earnings Per Share [Text Block] | 3. Earnings per share Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Dec. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | 4. Commitments and Contingencies Legal Claims The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products. The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient. Stuyvesant Falls Power Litigation. 469,000 492,000 696,000 The Company filed a Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara and the other party filed separate notices of appeal of the Court’s decision. On March 31, 2016 the Supreme Court of New York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer enforceable. The Company’s application for leave to appeal this ruling was dismissed as premature by the New York Court of Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion was granted on October 7, 2017 by the New York State Court of Appeals. The appellate decision terminated the enforceability of the free power covenants as of March 31, 2016. The appellate decision did not order the Company to pay any amounts for power consumed prior to such date and the Company believes that it is not liable for any such damages as a result of the appellate decision. On December 21, 2016, Niagara filed a motion to the trial court asking that it hold additional proceedings to establish what damages, if any, are owed to Niagara as the result of the appellate decision. The Company filed its response on January 23, 2017. On April 25, 2017, the court denied Niagara’s motion in its entirety finding that no damages could be awarded based on the Appellate Division’s decision. Niagara has filed a Notice of Appeal from that decision, but to date, has not filed the appeal. As of December 31, 2017, the Company has not recorded a provision for this matter. The Company commenced paying for power at the Stuyvesant Falls facility in April 2016. Employment Contract The Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement. |
Financing
Financing | 6 Months Ended |
Dec. 31, 2017 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | 5. Financing On February 27, 2017, Allied Healthcare Products, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Credit Agreement”) with Summit Financial Resources, L.P. (“Summit”) pursuant to which the Company obtained a secured revolving credit facility (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible, pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based on the Company’s accounts receivable and inventory but will not exceed $ 2,000,000 2,000,000 The Credit Facility will be available, subject to its terms, on a revolving basis until it expires on February 27, 2019 2.00 0.47 Regardless of the amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility, the Company will be obligated to pay an amount equal to twelve months of minimum monthly payments, minus the number of months elapsed since the effective date of the Credit Agreement. Under the Credit Agreement, advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage in a change of control, dissolve or wind up the Company. The Credit Agreement also contains certain events of default including, without limitation: the failure to make payments when due; the material breach of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company, appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment of any state or federal tax lien; attachment or levy upon or seizure of the Company’s property; or any change in the Company’s condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 20.00 At December 31, 2017, the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt. The prime rate as reported in the Wall Street Journal was 4.50 The Company was in compliance with all of the covenants associated with the Credit Facility at December 31, 2017. |
Income Taxes
Income Taxes | 6 Months Ended |
Dec. 31, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | 6. Income Taxes The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. In the three and six months ended December 31, 2017 the Company recorded the tax benefit of losses incurred in the amount of approximately $ 75,000 367,000 For the three and six months ended December 31, 2016 the Company recorded the tax benefit of losses incurred in the amount of approximately $ 130,000 436,000 130,000 436,000 U.S. Tax Reform On December 22, 2017, President Trump signed into law new tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “TCJA”), which became effective January 1, 2018. The TCJA significantly revises U.S. tax law by, among other provisions lowering the U.S. federal statutory income tax rate from 35 21 ASC Topic 740, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) on December 22, 2017, which allows companies to record the tax effects of the TCJA on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. During the second quarter of fiscal 2018, the Company recorded a one-time charge of $ 136,386 0 0 56 13 0.03 |
Summary of Significant Accoun12
Summary of Significant Accounting and Reporting Policies (Policies) | 6 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued Accounting Guidance In May 2014, the FASB and International Accounting Standards Board jointly issued new principles-based accounting guidance for revenue recognition that will supersede virtually all existing revenue guidance. The core principle of this guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. To achieve the core principle, the guidance establishes the following five steps: 1) identify the contract(s) with a customer, 2) identify the performance obligation in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also details the accounting treatment for costs to obtain or fulfill a contract. Lastly, disclosure requirements have been enhanced to provide sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB affirmed its proposal to defer the effective date by one year. In May 2016, the FASB issued improvements and practical expedients to the standard that included clarification of the collectability criterion, noncash considerations as well as clarification of options at transition. In December 2016, the FASB issued additional corrections and improvements. The Company is in the process of evaluating the impact of this guidance. This new guidance, will likely result in a change in the nature and extent of the related footnote disclosures. The Company plans to adopt the new guidance when effective and presently anticipates adopting on a modified retrospective basis to each prior reporting period presented with the election of applicable practical expedients. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments. |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Dec. 31, 2017 | |
Inventory, Net [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | Inventories are comprised as follows: December 31, 2017 June 30, 2017 Work-in progress $ 472,699 $ 468,839 Component parts 7,902,227 7,271,908 Finished goods 2,320,593 2,368,855 Reserve for obsolete and excess inventories (1,589,331) (1,597,648) $ 9,106,188 $ 8,511,954 |
Inventories (Details)
Inventories (Details) - USD ($) | Dec. 31, 2017 | Jun. 30, 2017 |
Inventory [Line Items] | ||
Work-in progress | $ 472,699 | $ 468,839 |
Component parts | 7,902,227 | 7,271,908 |
Finished goods | 2,320,593 | 2,368,855 |
Reserve for obsolete and excess inventories | (1,589,331) | (1,597,648) |
Inventory, Net | $ 9,106,188 | $ 8,511,954 |
Earnings per share (Details Tex
Earnings per share (Details Textual) - shares | 3 Months Ended | 6 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Earnings Per Share [Line Items] | ||||
Weighted Average Number of Shares Outstanding, Basic and Diluted | 4,013,537 | 4,013,537 | 4,013,537 | 4,013,537 |
Commitments and Contingencies (
Commitments and Contingencies (Details Textual) - USD ($) | Mar. 14, 2014 | Feb. 06, 2012 | Mar. 31, 2015 |
Commitments and Contingencies [Line Items] | |||
Loss Contingency, Damages Sought, Value | $ 492,000 | $ 469,000 | $ 696,000 |
Financing (Details Textual)
Financing (Details Textual) - USD ($) | 1 Months Ended | 6 Months Ended |
Feb. 27, 2017 | Dec. 31, 2017 | |
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | |
Line of Credit Facility, Expiration Date | Feb. 27, 2019 | |
Line of Credit Facility, Frequency of Payment and Payment Terms | the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum availability ($5,000 per month). | |
Summit Financial Resources Lp [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line Of Credit Facility, Maximum Borrowing Capacity | $ 2,000,000 | |
Debt Instrument, Basis Spread on Variable Rate | 2.00% | |
Line of Credit Facility, Remaining Borrowing Capacity | $ 2,000,000 | |
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.47% | |
Summit Financial Resources Lp [Member] | Revolving Credit Facility [Member] | Prime Rate [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate, Effective Percentage | 4.50% |
Income Taxes (Details Textual)
Income Taxes (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Dec. 22, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Schedule Of Income Tax Disclosure [Line Items] | |||||
Deferred Other Tax Expense (Benefit) | $ 75,000 | $ 130,000 | $ 367,000 | $ 436,000 | |
Deferred Tax Assets Valuation Allowance Addition Amount | 130,000 | $ 436,000 | |||
Earnings Per Share, Basic and Diluted | $ 0.03 | ||||
Provision for income taxes | $ 136,386 | $ 0 | $ 136,386 | $ 0 | |
Minimum [Member] | |||||
Schedule Of Income Tax Disclosure [Line Items] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | ||||
Effective Income Tax Rate Reconciliation, Percent | 0.00% | 0.00% | |||
Maximum [Member] | |||||
Schedule Of Income Tax Disclosure [Line Items] | |||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 35.00% | ||||
Effective Income Tax Rate Reconciliation, Percent | 56.00% | 13.00% |